The efficacy of RG7356 has been investigated by Menke-van der Houven van Oordt and colleagues in a first-in-human phase I trial in patients with locally advanced or metastatic cancers expressing high levels of CD44, including melanoma. The gene discussed is CD44; the disease is melanoma.